Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

The document concludes that proper diagnosis and a multidisciplinary approach are crucial for managing Congenital Adrenal Hyperplasia effectively.

The conclusion is that early diagnosis and a multi-system treatment approach are crucial for managing PCOS and its associated health risks.

The unit area trichogram is a reliable method to assess hair loss and treatment response in people with androgenic alopecia by measuring hair density and thickness.

New hormonal contraceptives are safer, have fewer side effects, and offer health benefits for women.

Women with PCOS may take longer to get pregnant but can have a normal family size, and should manage their overall health to reduce long-term health risks.

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

Hair loss that spreads out can often fix itself or be treated by finding and handling the cause.

The conclusion is that managing androgen excess requires long-term treatment, including hormonal contraceptives and androgen blockers, with follow-up after six months.

Testosterone therapy seems safe for postmenopausal women for a few years, but more research is needed for long-term effects.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

Norgestimate is the most effective birth control progestin for reducing an enzyme linked to acne and excessive hair growth in women.

Hormonal treatments can help with acne but are not the first choice due to side effects and the need for careful patient selection.

Women with PCOS often have skin problems like excessive hair, acne, hair loss, and dark patches, which can be treated with hormonal and non-hormonal therapies.

Minoxidil and finasteride are effective for male hair loss, minoxidil for female hair loss, and various treatments like corticosteroids work for alopecia areata; treatment should be tailored to the individual.

Estrogens and SERMs can help with skin aging, but their safety and effectiveness need more research.

Hidradenitis suppurativa treatment should be tailored to the individual, with quitting smoking being important.

The conclusion is that the best initial treatment for hirsutism is usually oral contraceptives, with the addition of antiandrogens or insulin sensitizers if needed, and topical eflornithine or laser treatments as supplementary options.

Some drugs can cause hair loss, and stopping these drugs often leads to hair regrowth.

Different types of androgens bind differently to two receptors, AR1 and AR2, in Atlantic croaker's brain and ovarian tissues, suggesting these receptors may control different androgen actions in fish.

Hormone treatment for transgender patients may not need to be stopped before surgery, but more research is needed, especially on estrogen.

Menopause and aging can affect women's quality of life and sexuality, but hormone therapies may help alleviate these issues.

Some medications can cause hair loss, but stopping the drug usually leads to recovery within 3 months.

Researchers developed a method to detect hormone-blocking drugs in wastewater and found them in Beijing's sewage, suggesting they can survive sewage treatment.

The document concludes with guidance for doctors on diagnosing and treating hirsutism effectively and safely.

The document concludes that Nonclassic Congenital Adrenal Hyperplasia requires personalized treatment plans to manage symptoms and fertility, with glucocorticoids being a common therapy.

Short-term testosterone therapy in women seems safe with few mild side effects, but long-term effects need more research.

The combination of cyproterone acetate and testosterone enanthate is highly effective in preventing sperm production and could be a good reversible male contraceptive.

The document concludes that future heart disease research should account for sex-specific differences to improve diagnosis, treatment, and outcomes.

The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.